dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Biagetti Biagetti, Betina |
dc.contributor.author | Simó Canonge, Rafael |
dc.date.accessioned | 2022-05-02T12:01:48Z |
dc.date.available | 2022-05-02T12:01:48Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Biagetti B, Simò R. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications. Int J Mol Sci. 2021 Oct;22(20):11247. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/7419 |
dc.description | Dopamine; Lactotroph tumour; Prolactinoma |
dc.description.abstract | Prolactinoma has the highest incidence rate among patients with functional pituitary tumours. Although mostly benign, there is a subgroup that can be aggressive. Some clinical, radiological and pathology features have been associated with a poor prognostic. Therefore, it can be considered as a group of heterogeneous tumours. The aim of this paper is to give an overview of the molecular pathways involved in the behaviour of prolactinoma in order to improve our approach and gain deeper insight into the better understanding of tumour development and its management. This is essential for identifying patients harbouring aggressive prolactinoma and to establish personalised therapeutics options. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;22(20) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Hipòfisi - Tumors - Tractament |
dc.subject | Dopamina - Agonistes - Ús terapèutic |
dc.subject.mesh | Pituitary Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Dopamine Agonists |
dc.subject.mesh | /therapeutic use |
dc.title | Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms222011247 |
dc.subject.decs | neoplasias hipofisarias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | agonistas dopaminérgicos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.3390/ijms222011247 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34681905 |
dc.identifier.wos | 000715415400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |